John Violet

6.0k total citations · 3 hit papers
39 papers, 2.6k citations indexed

About

John Violet is a scholar working on Radiology, Nuclear Medicine and Imaging, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, John Violet has authored 39 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Radiology, Nuclear Medicine and Imaging, 28 papers in Pulmonary and Respiratory Medicine and 12 papers in Oncology. Recurrent topics in John Violet's work include Radiopharmaceutical Chemistry and Applications (27 papers), Prostate Cancer Treatment and Research (25 papers) and Medical Imaging Techniques and Applications (6 papers). John Violet is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (27 papers), Prostate Cancer Treatment and Research (25 papers) and Medical Imaging Techniques and Applications (6 papers). John Violet collaborates with scholars based in Australia, United Kingdom and United States. John Violet's co-authors include Michael S. Hofman, Amir Iravani, Rodney J. Hicks, Declan G. Murphy, Shahneen Sandhu, Scott Williams, Grace Kong, Sue Ping Thang, Tim Akhurst and Price Jackson and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Clinical Endocrinology & Metabolism and The Lancet Oncology.

In The Last Decade

John Violet

38 papers receiving 2.6k citations

Hit Papers

[177Lu]-PSMA-617 radionuclide treatment in patients with ... 2018 2026 2020 2023 2018 2018 2018 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
    2018 815 citations Michael S. Hofman, John Violet et al. The Lancet Oncology profile →
  2. Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes
    2018 339 citations John Violet, Price Jackson et al. Journal of Nuclear Medicine profile →
  3. Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial
    2018 222 citations Shankar Siva, Mathias Bressel et al. European Urology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John Violet Australia 19 1.9k 1.8k 720 319 238 39 2.6k
James B. Stubbs United States 20 772 0.4× 1.3k 0.7× 344 0.5× 209 0.7× 200 0.8× 45 1.9k
Nitin Vaishampayan United States 5 1.2k 0.6× 1.1k 0.6× 573 0.8× 179 0.6× 200 0.8× 12 1.8k
Aviral Singh Germany 27 1.1k 0.6× 1.4k 0.8× 1.2k 1.7× 141 0.4× 158 0.7× 62 2.3k
David Binns Australia 34 1.3k 0.7× 1.9k 1.1× 545 0.8× 311 1.0× 655 2.8× 72 3.3k
Franz Josef Gildehaus Germany 20 651 0.3× 972 0.5× 328 0.5× 247 0.8× 99 0.4× 58 1.7k
Matthias Miederer Germany 25 705 0.4× 1.4k 0.8× 780 1.1× 281 0.9× 93 0.4× 84 2.4k
Frank Roesch Germany 25 544 0.3× 1.5k 0.8× 993 1.4× 249 0.8× 230 1.0× 104 2.2k
Anastasia Nikolopoulou United States 24 657 0.4× 1.4k 0.8× 892 1.2× 302 0.9× 62 0.3× 52 2.0k
Madhav Prasad Yadav India 22 677 0.4× 1.1k 0.6× 963 1.3× 164 0.5× 255 1.1× 59 1.8k
Shinji Kawabata Japan 33 899 0.5× 2.3k 1.3× 282 0.4× 364 1.1× 107 0.4× 173 3.8k

Countries citing papers authored by John Violet

Since Specialization
Citations

This map shows the geographic impact of John Violet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Violet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Violet more than expected).

Fields of papers citing papers by John Violet

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Violet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Violet. The network helps show where John Violet may publish in the future.

Co-authorship network of co-authors of John Violet

This figure shows the co-authorship network connecting the top 25 collaborators of John Violet. A scholar is included among the top collaborators of John Violet based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Violet. John Violet is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Alghazo, Omar, Renu Eapen, Nattakorn Dhiantravan, et al.. (2021). Study of the dosimetry, safety, and potential benefit of 177Lu-PSMA-617 radionuclide therapy prior to radical prostatectomy in men with high-risk localized prostate cancer (LuTectomy study).. Journal of Clinical Oncology. 39(6_suppl). TPS264–TPS264. 2 indexed citations
2.
Ferdinandus, Justin, John Violet, Shahneen Sandhu, et al.. (2020). Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617. European Journal of Nuclear Medicine and Molecular Imaging. 47(10). 2322–2327. 115 indexed citations
3.
Dhiantravan, Nattakorn, John Violet, Renu Eapen, et al.. (2020). Clinical Trial Protocol for LuTectomy: A Single-arm Study of the Dosimetry, Safety, and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy. European Urology Focus. 7(2). 234–237. 37 indexed citations
4.
Iravani, Amir, John Violet, Arun Azad, & Michael S. Hofman. (2019). Lutetium-177 prostate-specific membrane antigen (PSMA) theranostics: practical nuances and intricacies. Prostate Cancer and Prostatic Diseases. 23(1). 38–52. 49 indexed citations
5.
Hofman, Michael S., Louise Emmett, John Violet, et al.. (2019). TheraP: a randomized phase 2 trial of 177 Lu‐ PSMA ‐617 theranostic treatment vs cabazitaxel in progressive metastatic castration‐resistant prostate cancer (Clinical Trial Protocol ANZUP 1603). British Journal of Urology. 124(S1). 5–13. 108 indexed citations
6.
Jackson, Price, Michael S. Hofman, Rodney J. Hicks, Mark Scalzo, & John Violet. (2019). Radiation Dosimetry in 177Lu-PSMA-617 Therapy Using a Single Posttreatment SPECT/CT Scan: A Novel Methodology to Generate Time- and Tissue-Specific Dose Factors. Journal of Nuclear Medicine. 61(7). 1030–1036. 84 indexed citations
7.
Siva, Shankar, Mathias Bressel, Declan G. Murphy, et al.. (2018). Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial. European Urology. 74(4). 455–462. 222 indexed citations breakdown →
8.
Hofman, Michael S., John Violet, Rodney J. Hicks, & Shahneen Sandhu. (2018). [Lu-177]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer reply. The Lancet Oncology. 19(8). 1 indexed citations
9.
10.
Hanson, Erik D., Samy Sakkal, William S. Evans, et al.. (2018). Altered stress hormone response following acute exercise during prostate cancer treatment. Scandinavian Journal of Medicine and Science in Sports. 28(8). 1925–1933. 10 indexed citations
11.
Hofman, Michael S., John Violet, Rodney J. Hicks, et al.. (2018). [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. The Lancet Oncology. 19(6). 825–833. 815 indexed citations breakdown →
12.
Hofman, Michael S., John Violet, Shahneen Sandhu, et al.. (2018). High activity, pain reduction and low toxicity with Lutetium-177 PSMA617 theranostics in metastatic castrate-resistant prostate cancer (mCRPC): results of a phase II prospective trial. 59. 531–531. 3 indexed citations
13.
Hanson, Erik D., André R. Nelson, Daniel W. D. West, et al.. (2017). Attenuation of Resting but Not Load-Mediated Protein Synthesis in Prostate Cancer Patients on Androgen Deprivation. The Journal of Clinical Endocrinology & Metabolism. 102(3). 1076–1083. 26 indexed citations
14.
Lamboley, C. R., Hongyang Xu, T. L. Dutka, et al.. (2017). Effect of androgen deprivation therapy on the contractile properties of type I and type II skeletal muscle fibres in men with non‐metastatic prostate cancer. Clinical and Experimental Pharmacology and Physiology. 45(2). 146–154. 10 indexed citations
15.
Ferdinandus, Justin, John Violet, Shahneen Sandhu, & Michael S. Hofman. (2017). Prostate-specific membrane antigen theranostics. Current Opinion in Urology. 28(2). 197–204. 35 indexed citations
16.
Emery, Jon, Michael Jefford, Madeleine King, et al.. (2014). Protocol for the ProCare Trial: a phase II randomised controlled trial of shared care for follow-up of men with prostate cancer. BMJ Open. 4(3). e004972–e004972. 19 indexed citations
17.
Dancey, Gairin, John Violet, Alessandra Malaroda, et al.. (2009). A Phase I Clinical Trial of CHT-25 a 131I-Labeled Chimeric Anti-CD25 Antibody Showing Efficacy in Patients with Refractory Lymphoma. Clinical Cancer Research. 15(24). 7701–7710. 28 indexed citations
18.
Violet, John, et al.. (2008). Fractionated 131I anti-CEA radioimmunotherapy: effects on xenograft tumour growth and haematological toxicity in mice. British Journal of Cancer. 99(4). 632–638. 8 indexed citations
19.
Violet, John & Clive Harmer. (2004). Breast cancer: improving outcome following adjuvant radiotherapy. British Journal of Radiology. 77(922). 811–820. 22 indexed citations
20.
Chester, Kerry, R. Barbara Pedley, Berend Tolner, et al.. (2004). Engineering Antibodies for Clinical Applications in Cancer. Tumor Biology. 25(1-2). 91–98. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by James B. Stubbs Breakdown of academic impact, for papers by Nitin Vaishampayan Breakdown of academic impact, for papers by Aviral Singh Breakdown of academic impact, for papers by David Binns Breakdown of academic impact, for papers by Franz Josef Gildehaus Breakdown of academic impact, for papers by Matthias Miederer Breakdown of academic impact, for papers by Frank Roesch Breakdown of academic impact, for papers by Anastasia Nikolopoulou Breakdown of academic impact, for papers by Madhav Prasad Yadav Breakdown of academic impact, for papers by Shinji Kawabata
Rankless by CCL
2026